ZINC30303842(also known as NCGC00337199-01) is a novel and potent NSD2-PWWP1 antagonist.

UNC6852 (UNC-6852) is a novel PROTAC-based degrader PRC2 (polycomb repressive complex 2).

BIX-01338 is a novel and potent histone lysine methyltransferase G9a inhibitor with an IC50 value of 4.7µM. BIX01338 was discovered by high-throughput screening along with BIX0129434.

UNC3866 is a novel and potent antagonist of the methyllysine (Kme) reading function of the Polycomb CBX and CDY families of chromodomains with Kd of 100 nM as determined by AlphaScreen.

UNC0631 (UNC-0631) is a potent and selective inhibitor of histone methyltransferase G9a (KMT1C; EHMT2, IC50 = 4 nM) with antineoplastic activity.

MAK-683 (MAK683; extracted from patent US20160176882 A1, compound example 2) is a novel and potent embryonic ectoderm development protein (EED) inhibitor and allosteric inhibitor of polycomb repressive complex 2 (PRC2) with potential anticancer activity.

EPZ015666 (GSK-3235025), an analog of EPZ-015866, is a potent, selective and orally bioavailable inhibitor of PRMT5 (protein arginine methyltransferase) with antineoplastic activity.

EPZ015866 (also known as EPZ-015866; GSK-3203591; GSK-591) is an orally bioavailable and selective inhibitor of PRMT5 (protein arginine methyltransferase 5) with potential anticancer activity.

GSK343 is a novel, highly potent and selective inhibitor of H3-lysine 27 (H3K27) methyltransferase EZH2 with antineoplastic activity.

PFI-2 (PFI2) is a novel, potent and selective inhibitor of lysine methyltransferase SETD7 [SET domain containing (lysine methyltransferase) 7] with anticancer activity.